The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Annual EBITDA margin expands by 170 basis points
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
Subscribe To Our Newsletter & Stay Updated
